Immuno-Oncology T Cell Assays

Charles River’s translatable immuno-oncology platform enables oncology researchers to rapidly assess the T-cell-modulated immune function of therapeutic modalities in high-throughput and high-content imaging platforms illustrating T cell activation, increased T cell proliferation, T cell exhaustion, T cell chemotaxis, and cytokine response. Observe T-cell-mediated cytotoxicity in both 2D and 3D platforms. Start your biologic or small molecule on the road to discovery with our optimized T cell assays. Select T cell assays are available in an off-the-shelf format yielding results 3-5 weeks from receipt of compounds.

These simple and multicellular T cell assays are validated with standard of care molecules, including checkpoint inhibitors and a selection of small-molecule inhibitors of targets known to modulate immune responses, confirming Charles River’s predictive immuno-oncology platform. This comprehensive panel of T cell assays addresses every step of the cancer-immunity cycle.

cancer-immunity cycle, immuno-oncology assay translational platfrom

Download Cancer-Immunity Cycle Poster

A Translational Platform for Immunotherapeutics

T cell assays are used to generate information on compounds from each stage of the drug discovery process to inform and progress therapies rapidly from in vitro assays to in vivo studies and, ultimately, successfully to the clinic.

See the Data

Frequently Asked Questions (FAQ) for T Cell Assays

Interview with our Lead Oncology Scientist: Developing a Translational Immuno-Oncology Platform